1-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer

Verschraegen, Claire; Andric, Zoran G; ...; (broj, koautora 20)

Rezultati

eNauka > Rezultati > 1-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer

Naziv:	1-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer
Autori :	Verschraegen, Claire; Andric, Zoran G; ...; (broj, koautora 20)
Godina:	2022
Publikacija:	ANNALS OF ONCOLOGY
ISSN:	0923-7534 Annals of Oncology Pretraži identifikator
Tip rezultata:	Konferencijski rad
Kolacija:	vol. 33 br. 7 str. S1024-S1025
DOI:	10.1016/j.annonc.2022.07.1153
WoS-ID:	000866211601292
URI:	https://enauka.gov.rs/handle/123456789/823166
Projekat:	Celltrion Inc.
Izvor metapodataka:	(Preuzeto iz Nasi u WoS)
M-kategorija:	Mp kategorija će biti prikazana naknadno.

Alt metrika

Dimensions

Pronađi DOI

Pronalaženje DOI u servisu CrossRef-u na osnovu meta-podataka u zapisu. Prikazaće se DOI (i metapodaci) čiji se podaci najviše poklapaju. OPREZ - to ne mora biti ta publikacija.

Unpaywall

Google Scholar^TM

Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.